CEL-105
Women’s Health
HSDD
Pipeline
Development
Preclinical
Pre-IND
IND
Clinical
CEL-110
Women’s Health
VMS
CEL-200
Oncology
Melanoma*
Oncology
Cutaneous Carcinoma
Oncology
T-Cell Lymphoma*
Infectious Disease
RSV
Infectious Disease
Influenza
HPV Disease
RRP
HPV Disease
Cervical Cancer
HPV Disease
VIN*
Tropical Disease
Dengue
* Orphan Drug Designation from FDA
CEL-105
CEL-105 is an approved molecule which is being developed for a new indication and is delivered using Celista’s proprietary device and formulation technologies for accurate dosing and to ensure patient safety. Celista filed a pre-IND with the FDA in 2024.
CEL-110
CEL-110 is an approved molecule which is being developed for a new indication in a new form. It is delivered using Celista’s proprietary device and formulation technologies for accurate dosing and to ensure patient safety. Celista filed a preIND with the FDA in 2024.
CEL-200
CEL-200 is a proprietary TLR7/8 agonist and immunotherapy agent, this class of molecule is active against multiple disease types.
Contact us to discuss investment and partnership opportunities or to learn more about Celista Pharmaceuticals.